Make germline genetic testing easier for people with breast, pancreatic, or colorectal cancer
Official title: Increasing Germline Genetic Testing for Patients With Cancer
Run by Vanderbilt University Medical Center · NCT07307664 · Data updated 2026-11-12
This project tries a set of clinic changes to see if oncology teams will order more germline genetic tests for people with breast, pancreatic, or colorectal cancer.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Vanderbilt University Medical Center Academic / other |
| Locations | 10 sites (Los Angeles, California and 9 other locations) |
| Status | Recruiting |
| Started | January 30, 2026 |
| Main results expected | January 1, 2030 |
| Study ends | January 1, 2030 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT07307664 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with breast cancer, pancreatic cancer, or colorectal cancer who meet guideline criteria for hereditary (germline) testing are the ideal candidates to benefit from this work.
✕Probably not a fit
Patients with cancer types outside breast, pancreatic, or colorectal cancer, those who already had guideline-based germline testing, or those receiving care outside the participating VA sites are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The Genomics-enabled Learning Health Systems network will deploy a bundled set of implementation strategies aimed at ‘mainstreaming’ germline testing so oncology care teams can directly order tests. Different strategy bundles will be rolled out across participating VA sites in three consecutive 6-month phases, followed by a maintenance phase to see whether effects persist without extra support. Primary outcomes include rates of guideline-concordant test ordering by clinicians and secondary outcomes include patient completion of testing and overall testing rates. The interventions target clinician- and workflow-level factors rather than individual patient treatments.
Why it matters
Potential benefit: If successful, more patients who meet guidelines could receive germline testing, enabling targeted therapies, earlier surveillance, and cascade testing of family members.
How similar studies have gone: Previous single-site and smaller multisite mainstreaming programs have increased testing uptake, but large multisite learning health system deployments of bundled implementation strategies remain relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Oncology care team members (including, but not limited to, oncologists, advanced practice providers, nurse navigators, caring for patients with adult patients with breast cancer, pancreatic cancer or colorectal cancer. Exclusion Criteria: * Providers not on the oncology care team
Where it's running
-
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States Recruiting -
Orlando VA Medical Center
Orlando, Florida, United States Recruiting -
Atlanta VA Medical Center
Decatur, Georgia, United States Recruiting -
Northwestern Medicine
Chicago, Illinois, United States Recruiting -
Indiana University School of Medicine
Indianapolis, Indiana, United States Recruiting -
Durham VA Medical Center
Durham, North Carolina, United States Recruiting
Show 4 more locations
-
Salisbury VA Health Care System
Salisbury, North Carolina, United States Recruiting -
Geisinger
Danville, Pennsylvania, United States Recruiting -
Vanderbilt University Medical Center
Nashville, Tennessee, United States Recruiting -
University of Utah Health
Salt Lake City, Utah, United States Recruiting
Study contacts
- Principal investigator: Josh F Peterson, MD, MPH — Vanderbilt University Medical Center
- Study coordinator: Megan He, PhD
- Email: megan.he@vumc.org
- Phone: 615-875-9641
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
Assessing Lynch Syndrome Frequency in Colorectal Cancer Patients
This study is trying to find out how common Lynch syndrome is in people with colorectal cancer in Russia by looking at their blood and tumor samples over five years.
-
Parasite and Infestation Experience: Understanding What People Feel and Think
This observational study tests how people who strongly believe they have parasites or infestation feel and think, even when doctors say otherwise.
-
Corticosteroid for Diabetic Macular Edema (DME) in Adults with Diabetic Retinopathy
This trial tests whether intravitreal corticosteroid injections can influence inflammatory biomarkers and improve DME in adults with type 2 diabetes.
-
Non-invasive test to predict early heart rejection in pediatric transplant patients
This study tests non-invasive heart tests like cardiac MRI and blood markers to see if they can detect rejection in kids after heart transplant, potentially reducing the need for invasive biopsies.
-
AR-guided resection planning for head and neck tumors
Aims to see if augmented reality guidance can help surgeons perform more precise re-sections in head and neck tumor cases using cadaver specimens.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.